My watch list
my.bionity.com  
Login  

Capital MS&L

News Capital MS&L

  • Evolva completes Abunda acquisition

    Evolva Holding SA announced that it completed the acquisition of Abunda Nutrition, Inc. , after which it will be a wholly-owned subsidiary of Evolva.Evolva’s shareholders approved the capital increase required for the acquisition in the Annual General Meeting (“AGM”) of Evolva on 18 May 2011. As ann more

  • Photocure initiates enrolment into phase II trial of Cevira® for cervical HPV infection

    Photocure ASA has initiated patient enrolment in the first trial to evaluate the optimal dose and safety of Cevira, an integrated intravaginal drug-delivery device.The study is a randomized, placebo controlled dose finding study in patients with low to moderate grade cervical intraepithelial neoplas more

  • Evolva to receive first milestone payment from Roche

    Evolva Holding SA announced that Roche has confirmed that Evolva has achieved its first milestone in their collaboration. Roche will now make a corresponding milestone payment (of an undisclosed amount) to Evolva. The milestone relates to the achievement of diverse, purified active compounds that de more

All news on capital ms&l

Websites Capital MS&L

CONTACTS

Printable version About us Our Products R & D Partnerships People Investor & Media   CONTACTS Headquarters Transgene SA Boulevard Gonthier d’Andernach Parc d’Innovation – CS80166 F-67405 Illkirch-Graffenstaden Phone: +33 (0)3 88 27 91 00 Fax:     +33 (0)3 88 27 91 11       Investor Relations Press R more

News - Almac Discovery

Almac Discovery Almac Discovery News Introduction People Pipeline Target Finding Partnering and Collaboration News Careers Contact Us Almac Discovery announce commencement of Phase I trials of Granisetron Nasal Spray Innovative new technology could provide fast acting and convenient nausea relief fo more

PR-US 21-11-2008 TG1042 version finale

Société anonyme au capital de 50.555.029 € – R.C. Strasbourg B 317 540 581 11, rue de Molsheim – 67082 Strasbourg Cedex (France) Tél : + 33 03 88 27 91 00 Fax : + 33 03 88 27 91 11 www.transgene.fr Transgene’s TG1042 meets primary end point in step one of cutaneous B-cell lymphoma Phase more

All websites on capital ms&l

Watchlist

This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE